← Back to Search

Monoclonal Antibodies

Bimekizumab for Psoriatic Arthritis (BE OPTIMAL Trial)

Phase 3
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline until safety follow-up (up to week 72)
Awards & highlights

BE OPTIMAL Trial Summary

This study is evaluating whether a drug called bimekizumab can help treat psoriatic arthritis.

Eligible Conditions
  • Psoriatic Arthritis

BE OPTIMAL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline until safety follow-up (up to week 72)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline until safety follow-up (up to week 72) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
American College of Rheumatology (ACR) 50 response at Week 16
Secondary outcome measures
American College of Rheumatology (ACR) 20 response at Week 16
American College of Rheumatology (ACR) 70 response at Week 16
Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16
+16 more

BE OPTIMAL Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Bimekzumab dosage regimenExperimental Treatment2 Interventions
Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
Group II: Adalimumab dosage regimenActive Control1 Intervention
Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.
Group III: PlaceboPlacebo Group2 Interventions
Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bimekizumab
2018
Completed Phase 3
~6510

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
101 Previous Clinical Trials
20,571 Total Patients Enrolled
7 Trials studying Psoriatic Arthritis
2,953 Patients Enrolled for Psoriatic Arthritis
UCB CaresStudy Director001 844 599 2273
205 Previous Clinical Trials
44,098 Total Patients Enrolled
11 Trials studying Psoriatic Arthritis
3,214 Patients Enrolled for Psoriatic Arthritis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
2019. "A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03895203.
~142 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top